Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IP6K1 | Q92551 | 8/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 5/20 | 0.39 |
| ▸ | RXRA | P19793 | 4/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.38 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24451644 | 1.00 | IP6K1 (0.40) | IP6K1NR1H2RXRANR1H3MEN1 | |
| SCHEMBL24454022 | 0.89 | IMPDH2 (0.40) | IP6K1NR1H2RXRANR1H3MEN1 | |
| SCHEMBL24451648 | 0.89 | IMPDH2 (0.40) | IP6K1NR1H2RXRANR1H3MEN1 | |
| SCHEMBL29616596 | 0.88 | NR1H2 (0.39) | NR1H2RXRANR1H3MEN1KMT2A | |
| SCHEMBL31036479 | 0.88 | NR1H2 (0.39) | NR1H2RXRANR1H3KMT2A | |
| SCHEMBL27034795 | 0.88 | NR1H2 (0.39) | NR1H2RXRANR1H3MEN1KMT2A | |
| SCHEMBL30917881 | 0.88 | NR1H2 (0.39) | NR1H2RXRANR1H3MEN1KMT2A | |
| SCHEMBL30599282 | 0.86 | NR1H2 (0.48) | NR1H2RXRANR1H3 | |
| SCHEMBL24403239 | 0.86 | NR1H2 (0.48) | NR1H2RXRANR1H3 | |
| SCHEMBL24403238 | 0.86 | NR1H2 (0.48) | NR1H2RXRANR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11384090-B2 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-11352363-B1 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20220162216-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2022-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11384090-B2 | Spiropyrrolidine derived antiviral agents | ACE, ACE2, REN | IP6K1 2196/4885NR1H2 617/4885RXRA 4813/4885 |
| US-20220162216-A1 | NOVEL SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ACE, ACE2, REN | IP6K1 1813/4885NR1H2 460/4885RXRA 4740/4885 |
| US-11352363-B1 | Spiropyrrolidine derived antiviral agents | ACE, ACE2, REN | IP6K1 2204/4885NR1H2 889/4885RXRA 4810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.